Seattle Biotech Vedana Therapeutics Raises $46 Million to Develop Injectable Migraine Treatments

Seattle biotech Vedana Therapeutics raised $46 million in funding to develop injectable migraine treatments and plans to start Phase 1 trials next year under CEO Anurag Agarwal. The company has launched out of stealth mode to pursue its migraine therapy development.

More: FinSMEs

No comments yet.